Evotec SE (EVO)

NASDAQ: EVO · Real-Time Price · USD

2.000

+0.050 (2.56%)

At close: Aug 7, 2026, 4:00 PM EDT

2.011

+0.011 (0.56%)

Pre-market: Aug 10, 2026, 5:01 AM EDT

Evotec SE Financials Overview

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	745.04	788.37	796.97	781.43	751.45	618.03
Revenue Growth	-5.48%	-1.08%	1.99%	3.99%	21.59%	23.38%
Gross Profit	85.43	114.22	114.88	175.05	174.07	151.54
Operating Income	-157.6	-56.22	-142.52	-47.51	20.85	41
Net Income	-193.88	-103.52	-196.08	-83.91	-175.66	215.51
Earnings Per Share	-0.54	-0.29	-0.56	-0.23	-0.49	0.65
EPS Growth	-	-	-	-	-	3150.00%

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Discovery and Preclinical Development	508.59	529.28	611.55	672.98	702.02	-
Just - Evotec Biologics	237.04	259.59	186.62	108.45	49.43	-
Intersegment Elimination	-0.59	-0.5	-1.21	-	-	-139.12
Total	745.04	788.37	796.97	781.43	751.45	618.03

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	444.76	476.39	396.8	604.11	718.49	858.23
Total Debt	387.46	448.73	443.54	626.21	513.76	512.92
Net Cash (Debt)	57.3	27.66	-46.74	-22.1	204.73	345.32
Net Cash Growth	-	-	-	-	-40.71%	-
Net Cash Per Share	0.16	0.08	-0.13	-0.06	0.58	1.04

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	18.71	-9.18	18.22	36.44	203.11	122.24
Capital Expenditures	-58.51	-72.54	-117.47	-213.32	-181.35	-118.94
Free Cash Flow	-39.79	-81.72	-99.25	-176.88	21.75	3.29
Free Cash Flow Growth	-	-	-	-	560.35%	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	11.47%	14.49%	14.41%	22.40%	23.16%	24.52%
Operating Margin	-21.15%	-7.13%	-17.88%	-6.08%	2.77%	6.63%
Pretax Margin	-24.04%	-11.01%	-24.34%	-10.31%	-20.49%	38.34%
Profit Margin	-26.02%	-13.13%	-24.60%	-10.74%	-23.38%	34.87%
FCF Margin	-5.34%	-10.37%	-12.45%	-22.64%	2.89%	0.53%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	-	-	32.13
P/FCF Ratio	-	-	-	-	122.71	2239.57
PS Ratio	0.83	1.18	1.78	4.81	3.55	11.94